Antibiotic resistance: how scientists revived a powerful drug that superbugs had defeated

For decades, vancomycin has served as one of medicine's most trusted last-resort antibiotics, the drug doctors reach for when other treatments have failed against serious bacterial infections. But like many antibiotics before it, vancomycin has gradually lost ground to bacteria that evolved ways to resist it, leaving clinicians with fewer options for some of the most dangerous drug-resistant infections. Now, researchers say they have found a way to restore the drug's killing power, not by inventing a new antibiotic, but by giving the old one a chemical partner.

Antibiotic resistance develops when bacteria are repeatedly exposed to a drug and the small fraction of the population with a natural genetic advantage survives and reproduces, gradually making the drug less effective across the wider bacterial population. Enterococcus faecium, a bacterium that can cause serious bloodstream and wound infections, particularly in hospitalized patients, is among the pathogens that developed strong resistance to vancomycin, turning what was once a reliable treatment into an unreliable one for an increasing share of cases.

Rather than developing an entirely new antibiotic from scratch, a process that typically takes many years and enormous investment, researchers pursued a different strategy: identifying the specific mechanism the bacteria use to resist vancomycin and then designing a molecule to disable that mechanism directly. This approach, sometimes called a resistance-breaker or adjuvant strategy, has become an increasingly active area of antibiotic research precisely because developing new antibiotics from scratch has become commercially and scientifically difficult.

The molecule the researchers paired with vancomycin, referred to as pghi-4, works by blocking a bacterial enzyme that plays a central role in the resistance mechanism. Resistant strains of E. faecium alter the molecular structure that vancomycin normally targets, effectively hiding from the drug. By interfering with the enzyme responsible for that structural change, pghi-4 appears to prevent the bacteria from completing the alteration, leaving vancomycin's usual target exposed and vulnerable again.

In laboratory testing, the combination of vancomycin and pghi-4 restored the antibiotic's ability to kill drug-resistant E. faecium, a result that would not have been possible with vancomycin alone against these particular resistant strains. The researchers describe the finding as evidence that resistance mechanisms, once understood at a molecular level, can sometimes be directly countered rather than requiring an entirely new drug to route around them.

The strategy is not without precedent. A similar combination approach has already reshaped treatment for other resistant infections: certain antibiotics are now routinely paired with a second compound whose only job is to block the bacterial enzyme that would otherwise destroy the antibiotic before it can act. Those combination drugs are now standard treatments for a range of resistant bacterial infections, offering a template that researchers hope to replicate with vancomycin and other older antibiotics facing similar resistance problems.

Reviving existing antibiotics through combination therapy carries a significant practical advantage over developing new drugs from scratch: it can potentially reach patients much faster. Vancomycin's safety profile, dosing, and side effects are already well understood after decades of clinical use, meaning a combination therapy built around it would likely face a shorter and less uncertain path through clinical trials than an entirely novel compound.

Antimicrobial resistance has been described by global health bodies as one of the most significant long-term threats to modern medicine, undermining not just the treatment of infections themselves but also the safety of routine procedures like surgery and chemotherapy, which rely on antibiotics to prevent secondary infections. The pipeline of genuinely new antibiotic classes has slowed considerably in recent decades, as the economics of antibiotic development, drugs typically taken for a short course rather than a lifetime, have made the field less commercially attractive than treatments for chronic disease.

That economic reality is part of why the resistance-breaker approach has drawn growing scientific interest: it offers a route to meaningful clinical improvement that does not require the multi-billion-dollar investment associated with an entirely new antibiotic class. If pghi-4 or similar molecules prove safe and effective in further testing, they could extend the usable life of vancomycin and potentially other older antibiotics whose resistance mechanisms can be mapped and specifically countered.

The vancomycin findings remain at the laboratory stage, and researchers caution that results in bacterial cultures do not guarantee similar success in human patients, where dosing, drug interactions, and the complexity of real infections introduce variables a lab dish cannot capture. Still, in a field where genuinely new treatment options have become rare, restoring the power of a drug doctors already trust represents a meaningful step forward, and a reminder that not every advance against superbugs needs to start from zero.